Dr. Muss Discusses Tamoxifen as Breast Cancer Prevention

Video

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses tamoxifen as breast cancer prevention

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses tamoxifen as breast cancer prevention.

Muss says breast cancer prevention is difficult. Many of the studies that have looked at tamoxifen or aromatase inhibitors as breast cancer prevention have shown that these agents prevent breast cancer, but don’t save any lives. What these studies show is that many of the people that develop breast cancer were able to survive the disease, Muss says.

Muss says the decision to use prevention depends on the patient’s average risk. Understanding the patient’s risk can help determine the potential benefits of these prevention drugs since these drugs come with side effects.

These breast cancer prevention drugs provide the most benefit to premenopausal younger patients or older women who have had a hysterectomy, Muss says.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.